To replicate the association of variants in RYR3 gene with common carotid intima-media thickness (cIMT), a surrogate marker of atherosclerosis, we genotyped single nucleotide polymorphisms (SNPs) rs2229116 and rs7177922 in a sub-population of 244 HIV-positive and HIV-negative men. SNP rs2229116 was associated with common cIMT in HIV infected white men after adjusting for age and use of stavudine (d4T). The association was more evident at younger ages and decreased among older individuals.
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Life expectancy of people with HIV infection has been greatly extended with the effective use of highly active antiretroviral therapy (HAART). However, atherosclerotic vascular disease is emerging as an important complication in HIV patients [1] [2] [3] [4] . Carotid intimamedia thickness (cIMT), a surrogate marker of atherosclerosis, is consistently higher among HIV-positive patients than HIV-negative controls [5] [6] [7] and comparable to coronary artery disease patients [8] . There is evidence that genetic variation contributes to variation in cIMT. The initial genome-wide association (GWA) study in 177 HIV þ white men on HAART [all with history of stavudine (d4T) use] in the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study suggested that the ryanodine receptor 3 (RYR3) gene is linked to cIMT [9] . Two single nucleotide polymorphisms (SNPs), rs2229116 and rs7177922, in tight linkage disequilibrium (LD; r 2 ¼ 0.97), were significantly associated with the common cIMT (P < 3.4 Â 10 À8 and P < 2.74 Â 10 À8 , respectively). The rs2229116 SNP is a nonsynonymous polymorphism, with a residue change of Ile!Val resulting from the A!G nucleotide substitution in the sequence. Individuals with the rs2229116GG genotype showed significantly higher common cIMT than those with AA or AG genotypes [9] .
To follow-up and replicate the previous study finding, we genotyped rs2229116 and rs7177922 in 244 individuals (117 HIV þ and 97 HIV À whites, and 21 HIV þ and nine HIV À African-Americans) from the Pittsburgh site of the Multicenter AIDS Cohort Study (MACS) cardiovascular disease sub-study [7] . Briefly, high resolution B-mode carotid artery ultrasound was used to image the far wall of the right common carotid artery, internal carotid artery, and carotid bulb according to the procedure of Hodis et al. [10] . Sonographers were trained at the University of Southern California Atherosclerosis Research Unit Core Imaging and Reading Center. cIMT measurements were repeated in 38 healthy volunteers using this method, and the coefficient of variation was 1% (intraclass correlation coefficient ¼ 0.99). The study was restricted to men who were over 40 years and less than 300 lb, with no reported history of coronary heart disease. To replicate the previous GWA study from the FRAM study, we initially restricted the analysis to white men on HAART. Associations of the SNPs with cIMT were assessed using a linear regression model (additive model), adjusting for age and d4T, a nucleoside analog reverse transcriptase inhibitor associated with increased cIMT [11] , and other metabolic syndromes [12, 13] . We did not adjust for duration of HAART as data was not available for all participants. Further interactions of the genetic variants with both d4T and age were also assessed.
Among whites (median age ¼ 50.05 years), the minor allele frequency was 24.5% for rs2229116(G) and 22.7% for rs7177922(A). Neither SNP deviated from the Hardy-Weinberg equilibrium. Common cIMT was associated with rs2229116(G) (b ¼ 0.27 AE 0.13, P ¼ 0.05) in an additive model, consistent with the previous study. Further, the association seemed to be strongest earlier and decreased (b ¼ 0.005 AE 0.002 per year, P ¼ 0.045) as individuals aged ( Table 1 ). The significant interaction of rs2229116 with age is quite important as the prevalence of atherosclerosis is increasing among younger HIV patients on treatment. However, the association of this SNP was not apparent in a smaller set of HIV-negative whites and the analysis was limited among African-Americans (only one individual with GG). The association with rs7177922 was not statistically significant but trended in the same direction. The linkage disequilibrium between the two SNPs was quite high, but slightly lower than in the previous study (r 2 ¼ 0.90 vs. 0.97). Of note, LD between these two SNPs differs significantly in various populations, ranging from 0.01 to 1.00 in the 11 HapMap populations, with the highest linkage disequilibrium in Japanese-Asians and lowest in Yoruban-Africans.
RYR3 is a Ca 2þ channel that mobilizes stored Ca 2þ to initiate muscle contraction. RYR3 shares a high amino acid sequence identity (66-70%) with the RYR1 and RYR2 genes. The biological function and mechanism of the RYR3 gene is not as well known as RYR1 and RYR2. Only recently, RYR3 has been shown to be associated with few other diseases [14, 15] , but not with cardiovascular outcomes. On the contrary, RYR1/2 genes have been associated with various cardiovascular and heart-related mechanisms, thus it is very reasonable to speculate that the isoform RYR3 is biologically associated with cIMT. RYR3 is known to be coexpressed in Ca 2þ signaling mechanisms in the cardiac and skeletal muscles [14] and studies have shown its role in endothelial vasodilation in the human arterial endothelial cells [16] , which is compromised in atherosclerosis. Studies have suggested that Ca 2þ release through RYR3 is involved in vasodilatation of vascular smooth muscle cells (VSMCs), and any alteration of this release pathway would affect VSMC contractility [17] . RYR is also upregulated in the aorta of atherosclerosis-prone mice compared with atherosclerosis-resistant mice [18] . In terms of HIV, Tat gene in HIV-1 has been shown to cause endothelial dysfunction inducing rapid loss of endoplasmic reticulum Ca 2þ through the mediation of RYRs. It has also been reported that RYR3 is essential in the sustained Ca 2þ response in T cells [19] , the target cells of HIV.
Here, we report a replication study of the previous finding with common cIMT, however, with different measurement methodologies and readers between the two studies [4, 7] . Further investigation is required in other ethnic groups and HIV-negative individuals to differentiate whether the mechanism is driven through HIV infection and HAART or independently. One caution is that in other ethnic groups the frequency and the linkage disequilibrium pattern could vary in this large gene with 104 exons in chromosome 15q14-q15 of the human genome. As many as seven alternative spliced variants are known in RYR3 [20] . Even with our results from this replication study, it is unclear whether this SNP is directly related to cIMT or serves as a surrogate of one or more causal variants in linkage disequilibrium. Further studies cataloguing the complete list of functional variants (rare and common) and how they might be associated with these SNPs are needed to better understand the molecular mechanisms underlying the contribution of RYR3 to atherosclerosis. Little data exist regarding the association of epicardial adipose tissue (EAT) and cardiovascular disease among HIV-infected persons. Among 213 HIV-infected men, there was a significant association between protease inhibitor use and increasing EAT volume. EATwas significantly associated with coronary artery calcium greater than 100. The elevated coronary artery disease risk in HIVinfected men may be partially explained by EAT associated with protease inhibitor use.
HIV-infected persons have a heightened risk for coronary artery disease (CAD), and abdominal visceral adipose tissue is a described risk factor [1, 2] . Another type of visceral fat, epicardial adipose tissue (EAT), may promote a local proatherogenic environment resulting in the development of CAD [3, 4] . Studies in the general population have shown that EAT corresponds to the severity of CAD and predicts future cardiovascular events [3, 4] , but little data exist among HIV-infected persons [5, 6] , especially regarding the role of antiretroviral agents.
We conducted a cross-sectional study of factors associated with coronary artery calcium (CAC) among adult HIVinfected men [7] , including a substudy on the role of EAT. Data on demographics, substance use, medical conditions and HIV-specific factors (including antiretroviral agents) were collected. Body measurements included BMI, waist circumference and skin-fold thickness (subscapular, suprailiac, biceps and triceps using a standardized Lange skin-fold calipers) to calculate the percentage body fat [8] .
Fat gain in the abdominal, breast and/or neck areas by visual assessment was considered lipohypertrophy; weight loss in the cheeks, buttocks and/or legs was considered as lipoatrophy [9] . A fasting blood specimen was also collected.
All participants underwent a computed tomography (CT) scan on the same day as clinical and laboratory data collection to determine the CAC score and EAT volume. All imaging was performed on a single, multidetector 64-slice CT scanner (Siemens Definition Dual Source CT Scanner, Siemens Medical Solutions, Forsheim, Germany). Contrast media was not administered, and the estimated total radiation dose was 1.0 mSv. EAT was measured using the same images for CAC and defined as the hypodense rim surrounding the myocardium and limited by the pericardium as previously described [10, 11] ; tissue was measured that was À190 to À30 Hounsfield units, thus excluding any contribution from the coronary arteries, coronary calcium, blood or aorta (Fig. 1a ). We also found that the odds of CAC more than 100 increased with each quartile of EAT, with the highest quartile (>140 cm 3 ) being associated with a 10-fold higher odds (OR 10.4, 95% CI 1.27-85.28, P ¼ 0.03).
Statistics included linear regression analyses to examine
We also examined the relationship of having multivessel disease (among those with a CAC >0) and EAT volume, and found a significant association (OR 1.12 per 10 cm 3 , 95% CI 1.02-1.23, P ¼ 0.02).
In summary, EAT has rarely been considered in the pathogenesis of CAD among HIV-infected persons, but they may be at particular risk for excessive regional fat deposition due to antiretroviral therapy and inflammation. We found a novel association between protease inhibitor use and increasing EAT volume. Further, our study showed that increasing EAT volume was significantly associated with CAC scores more than 100, and that EAT was more strongly associated with CAC than traditional measures of fat.
The pathogenesis of EAT with positive CAC scores is likely several-fold. First, EAT is a type of visceral fat which is embryologically related to intra-abdominal fat, both are derived from brown adipose tissue in infancy [12] . Second, deposition of adipose tissue around the coronary vessels and the resultant proatherogenic milieu may contribute to CAD. For example, EAT may exert local toxic effects on the vasculature via production of inflammatory cytokines (e.g. tumor necrosis factor, interleukin 1, and interleukin 6) and inhibition of antiinflammatory adipokines (e.g. adiponectin) [13] . An outside-to-inside mechanism has been proposed in which EAT leads to adventitial inflammation (with vaso vasorum neovascularization) and subsequent endothelial dysfunction, thrombogenesis and plaque formation [14] . This hypothesis is supported by studies demonstrating that segments of coronary arteries lacking epicardial fat are typically without atherosclerotic lesions [15] .
This is the first study to show a relationship between EAT volume and duration of protease inhibitor use, and suggests that these medications may not only lead to abdominal visceral fat deposition, but also to fatty deposition in the epicardium. This study may provide an additional potential mechanism for the link between protease inhibitor use and CAD beyond that explained by dyslipidemia and abdominal fat accumulation.
Limitations include its cross-sectional design and that we did not study clinical cardiac events. We relied on visual assessments and abdominal measurements to define lipodystrophy rather than dual-energy X-ray absorptiometry scans. Additionally, an HIV-negative comparison group was not utilized. Finally, the number of patients with CAC was small, and further studies are warranted.
In summary, increasing EAT volume is associated with CAD as measured by CAC scores among HIV-infected persons. Understanding the precise role of HIV and antiretroviral therapy (especially protease inhibitors) on EAT deposition as well as the role of EAT progression on cardiac events should be the subject of future studies among HIV-infected persons. 
